Home » Stocks » FSTX

F-star Therapeutics, Inc. (FSTX)

Stock Price: $7.13 USD -1.74 (-19.62%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $6.87 -0.26 (-3.65%) May 7, 7:43 PM
Market Cap 64.89M
Revenue (ttm) 11.26M
Net Income (ttm) -25.62M
Shares Out 2.64M
EPS (ttm) -9.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $7.13
Previous Close $8.87
Change ($) -1.74
Change (%) -19.62%
Day's Open 7.10
Day's Range 6.85 - 7.90
Day's Volume 2,176,439
52-Week Range 1.15 - 15.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical company dedicate...

3 days ago - GlobeNewsWire

SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model

2 weeks ago - GlobeNewsWire

Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and Activation Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Effic...

4 weeks ago - GlobeNewsWire

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gener...

1 month ago - GlobeNewsWire

Company to Host Conference Call Today at 9 a.m. EDT Company to Host Conference Call Today at 9 a.m. EDT

1 month ago - GlobeNewsWire

Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.

Other stocks mentioned: APOP, EVFM, IMMP, PRQR
1 month ago - Benzinga

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gener...

2 months ago - GlobeNewsWire

F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value.

3 months ago - Seeking Alpha

Patent protects Company's lead clinical asset FS118 throughout Europe Patent protects Company's lead clinical asset FS118 throughout Europe

3 months ago - GlobeNewsWire

FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Company's third bispecific to enter clinical trials

4 months ago - GlobeNewsWire

CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to transform...

Other stocks mentioned: SBPH
5 months ago - PRNewsWire

HOPKINTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release reads: HOP...

Other stocks mentioned: SBPH
5 months ago - PRNewsWire

1-for-4 Reverse Stock Split to be Effective November 20, 2020 1-for-4 Reverse Stock Split to be Effective November 20, 2020

Other stocks mentioned: SBPH
5 months ago - GlobeNewsWire

HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncolog...

Other stocks mentioned: SBPH
6 months ago - GlobeNewsWire

HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammato...

Other stocks mentioned: SBPH
6 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in con...

Other stocks mentioned: SBPH
7 months ago - Business Wire

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SB...

Other stocks mentioned: SBPH
7 months ago - PRNewsWire

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc.

Other stocks mentioned: SBPH
8 months ago - PRNewsWire

Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs

Other stocks mentioned: SBPH
8 months ago - GlobeNewsWire

NEW ORLEANS, Aug. 6, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

Other stocks mentioned: SBPH
9 months ago - PRNewsWire

NEW YORK, Aug. 5, 2020 /PRNewswire/ --Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City,...

Other stocks mentioned: SBPH
9 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Spring Bank Ph...

Other stocks mentioned: SBPH
9 months ago - Business Wire

NEW YORK, July 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors violated...

Other stocks mentioned: SBPH
9 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed mer...

Other stocks mentioned: SBPH
9 months ago - Business Wire

New York, New York--(Newsfile Corp. - July 30, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilec...

Other stocks mentioned: SBPH
9 months ago - Newsfile Corp

HOPKINTON, Mass. and CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceuti...

Other stocks mentioned: SBPH
9 months ago - GlobeNewsWire

-    Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1...

Other stocks mentioned: SBPH
11 months ago - GlobeNewsWire

HOPKINTON, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflamm...

Other stocks mentioned: SBPH
1 year ago - GlobeNewsWire

Spring Bank Pharmaceuticals Inc. [s; sbph] said Wednesday it is scrapping the development of inarigivir soproxil, a treatment for chronic hepatitis B virus, after a patient died during a phase 2 trial.

Other stocks mentioned: SBPH
1 year ago - Market Watch

HOPKINTON, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vira...

Other stocks mentioned: SBPH
1 year ago - GlobeNewsWire

The upbeat sentiments prevailing in Wall Street make investment in small caps stocks attractive for 2020, here's why.

Other stocks mentioned: CHUY, CUBI, DKL, SBPH, UCTT
1 year ago - Zacks Investment Research

Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.

Other stocks mentioned: SBPH
1 year ago - Zacks Investment Research

Spring Bank Pharmaceutical Inc.'s shares slid 17% in premarket trade Thursday, after the clinical-stage biopharma company said it has stopped dosing patients in a trial of a treatment for chronic hepat...

Other stocks mentioned: SBPH
1 year ago - Market Watch

HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vira...

Other stocks mentioned: SBPH
1 year ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for December 24th

Other stocks mentioned: DKS, EVA, JOUT, SBPH
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals.

Other stocks mentioned: SBPH
1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for December 11th

Other stocks mentioned: EXPR, GCO, SBPH, SEAC
1 year ago - Zacks Investment Research

HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vira...

Other stocks mentioned: SBPH
1 year ago - GlobeNewsWire

HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vira...

Other stocks mentioned: SBPH
1 year ago - GlobeNewsWire

HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vir...

Other stocks mentioned: SBPH
1 year ago - GlobeNewsWire

HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vir...

Other stocks mentioned: SBPH
1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals, Inc. (SBPH).

Other stocks mentioned: SBPH
1 year ago - Zacks Investment Research

Today, we take an in-depth look at Spring Bank Pharmaceuticals.

Other stocks mentioned: SBPH
1 year ago - Seeking Alpha

About FSTX

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in C... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2016
Stock Exchange
NASDAQ
Ticker Symbol
FSTX
Full Company Profile

Financial Performance

In 2020, FSTX's revenue was $11.26 million, a decrease of -60.26% compared to the previous year's $28.32 million. Losses were -$25.62 million, 11.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for FSTX stock is "Strong Buy" and the 12-month stock price forecast is 26.00.

Price Target
$26.00
Analyst Consensus: Strong Buy